PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

NCT05172596 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
146
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated since the sponsor made the decision to discontinue further development of the study drug durcabtagene autoleucel (PHE885).

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals